Lopinavir Protein Binding In Vivo Through the 12-Hour Dosing Interval

Therapeutic Drug Monitoring

Volumn 26, Issue 1, 2004, Pages 35-39

  Boffito, Marta ^a,b,c   Hoggard, Patrick G ^a   Lindup, W Edward ^a   Bonora, Stefano ^b   Sinicco, Alessandro ^b   Khoo, Saye H ^a   Di Perri, Giovanni ^b   Back, David J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF TURIN   (Italy)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Lopinavir; Pharmacokinetics; Protease inhibitors; Protein binding; Unbound percentage

Indexed keywords

ABACAVIR; DIDANOSINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; OROSOMUCOID; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DOSE CALCULATION; DRUG MONITORING; EQUILIBRIUM DIALYSIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; PROTEIN BINDING; ULTRAFILTRATION; VIRUS LOAD;

ADULT; AREA UNDER CURVE; BLOOD PROTEINS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PROTEIN BINDING; PYRIMIDINONES; RITONAVIR; ULTRAFILTRATION;

EID: 0942297950     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200402000-00008     Document Type: Article

References (15)

1. Bilello JA, Drusano GL. Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease. J Infect Dis. 1996;173:1524-1526.
2. Back DJ, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS. 2002;16:85-837.
3. Anderson PL, Brundage RC, Bushman L, Kakuda TN, Remmel RP, Fletcher CV. IDV plasma protein binding in HIV-1-infected adults. AIDS. 2000;14:2293-2297.
4. Holladay JW, Dewey MJ, Michniak BB, et al. Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of SQV. Drug Metab Dispos. 2001;29:299-303.
5. Boffito M, Hoggard PG, Reynolds HE, et al. Unbound saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects. Br J Clin Pharmacol. 2002;54:262-268.
6. Herforth C, Stona JA, Jayewardene AL, et al. Determination of nelfinavir free drug concentrations in plasma by equilibrium dialysis and liquid chromatography/tandem mass spectometry: important factors for method optimization. Eur J Pharm Sci. 2002;15:185-195.
7. Aarnoutse RE, Schapiro JM, Boucher CAB, et al. Therapeutic drug monitoring. An aid to optimising response to antiretroviral drugs? Drugs. 2003;63:741-753.
8. Lindup WE. Plasma protein binding of drugs-some basic and clinical aspects, in Bridges JW, Chasseaud LF, Gibson GG, eds. Progress in Drug Metabolism, Vol 10 Philadelphia: Taylor & Francis, 1987:141-185.
9. Resnik L, Veren K, Salahuddin SZ, et al. Stability and inactivation of HTLV-III/LAV under clinical and laboratory enviroments. JAMA. 1986;255:1887-1891.
10. Tozer TN, Giambetoglio JG, Furst DE, et al. Volume shift and protein binding estimates using equilibrium dialysis: application to prednisolone binding in humans. J Pharm Sci. 1983;72:1442-1446.
11. Lowry OH, Rosenborough NJ, Farrar AL, et al. Protein measurement with Folin phenol reagent. J Biol Chem. 1951;193:265-275.
12. Giacomini KM, Wong FM, Tozer TN. Correction for volume shift during equilibrium dialysis by measurement of protein concentration. Pharm Res. 1984;4:179-181.
13. th Conference on Retroviruses and Opportunistic Infections, 2001.
14. 1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors. J Infect Dis. 1999;180:1833-1837.
15. Hervé F, Gomas E, Duché JC, et al. Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein. Br J Clin Pharmacol. 1993;36:241-249.